Page last updated: 2024-11-07

thiodigalactoside

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Thiodigalactoside, also known as TDG, is a synthetic analog of lactose. It is a powerful inducer of the lac operon in E. coli. TDG is synthesized by replacing the oxygen atom in the glycosidic linkage of lactose with a sulfur atom. This substitution prevents the compound from being hydrolyzed by β-galactosidase, making it a more stable inducer. TDG has been widely used in research to study the regulation of gene expression in E. coli. The compound is especially valuable for studying the lac operon because it provides a stable, non-hydrolyzable inducer that allows for the accumulation of high levels of β-galactosidase. TDG is also used to study the role of the lac operon in the metabolism of lactose. It is an important tool for understanding how bacteria respond to changes in their environment and regulate gene expression.'

thiodigalactoside: RN given refers to beta-D-galactopyranoside (D-Gal)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID119138
CHEMBL ID52011
SCHEMBL ID5520730
MeSH IDM0099689

Synonyms (29)

Synonym
(2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-{[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl]thio}tetrahydro-2h-pyran-3,4,5-triol
bdbm50077225
thiodigalactoside
1LT5
DB04396
CHEMBL52011 ,
80441-61-8
(2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanyloxane-3,4,5-triol
galactopyranosyl-1-thiogalactopyranoside
beta-d-galactopyranoside, d-galactosyl 1-thio-
gbtgp
galactosyl-1-thio-beta-d-galactopyranoside
tdg cpd
galactopyranosyl 1-thio-beta-d-galactopyranoside
galactosyl-beta-d-thiogalactosylpyranoside
galsgal
51555-87-4
4JC1
3OYW
SCHEMBL5520730
beta-d-galactopyranosyl 1-thio-beta-d-galactopyranoside
(2r,3r,4s,5r)-2-(hydroxymethyl)-6-{[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanyl}oxane-3,4,5-triol
(2r,2'r,3r,3'r,4s,4's,5r,5'r,6s,6's)-6,6'-thiobis(2-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol)
(2r,3r,4s,5r)-2-(hydroxymethyl)-6-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanyloxane-3,4,5-triol
AS-56930
AKOS037645087
CS-0105756
HY-130208
STARBLD0016696
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (14)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain D, HEAT-LABILE ENTEROTOXINEscherichia coliIC50 (µMol)2,000.00002,000.00002,000.00002,000.0000AID977608
Chain E, HEAT-LABILE ENTEROTOXINEscherichia coliIC50 (µMol)2,000.00002,000.00002,000.00002,000.0000AID977608
Chain D, Heat-labile EnterotoxinEscherichia coliIC50 (µMol)2,000.00002,000.00002,000.00002,000.0000AID977608
Chain E, Heat-labile EnterotoxinEscherichia coliIC50 (µMol)2,000.00002,000.00002,000.00002,000.0000AID977608
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Galectin-1Homo sapiens (human)Kd78.000078.000078.000078.0000AID977611
Chain A, Galectin-1Homo sapiens (human)Kd78.000078.000078.000078.0000AID977611
Galectin-8Homo sapiens (human)Kd61.00002.30002.30002.3000AID1628970; AID1908327; AID412878; AID513983
Galectin-3Homo sapiens (human)Kd47.80000.15000.22000.2900AID1628968; AID1908326; AID412876; AID513981; AID723493
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (87)

Processvia Protein(s)Taxonomy
regulation of interleukin-4 productionGalectin-9Homo sapiens (human)
regulation of interleukin-5 productionGalectin-9Homo sapiens (human)
toll-like receptor 2 signaling pathwayGalectin-9Homo sapiens (human)
toll-like receptor 4 signaling pathwayGalectin-9Homo sapiens (human)
mature conventional dendritic cell differentiationGalectin-9Homo sapiens (human)
regulation of p38MAPK cascadeGalectin-9Homo sapiens (human)
natural killer cell tolerance inductionGalectin-9Homo sapiens (human)
chemotaxisGalectin-9Homo sapiens (human)
inflammatory responseGalectin-9Homo sapiens (human)
female pregnancyGalectin-9Homo sapiens (human)
positive regulation of gene expressionGalectin-9Homo sapiens (human)
negative regulation of gene expressionGalectin-9Homo sapiens (human)
response to lipopolysaccharideGalectin-9Homo sapiens (human)
negative regulation of chemokine productionGalectin-9Homo sapiens (human)
negative regulation of type II interferon productionGalectin-9Homo sapiens (human)
negative regulation of tumor necrosis factor productionGalectin-9Homo sapiens (human)
positive regulation of type II interferon productionGalectin-9Homo sapiens (human)
positive regulation of interleukin-1 beta productionGalectin-9Homo sapiens (human)
positive regulation of interleukin-10 productionGalectin-9Homo sapiens (human)
positive regulation of interleukin-12 productionGalectin-9Homo sapiens (human)
positive regulation of interleukin-13 productionGalectin-9Homo sapiens (human)
positive regulation of interleukin-4 productionGalectin-9Homo sapiens (human)
positive regulation of interleukin-6 productionGalectin-9Homo sapiens (human)
positive regulation of interleukin-8 productionGalectin-9Homo sapiens (human)
positive regulation of tumor necrosis factor productionGalectin-9Homo sapiens (human)
positive regulation of CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation involved in immune responseGalectin-9Homo sapiens (human)
p38MAPK cascadeGalectin-9Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionGalectin-9Homo sapiens (human)
negative regulation of mast cell degranulationGalectin-9Homo sapiens (human)
negative regulation of natural killer cell mediated cytotoxicityGalectin-9Homo sapiens (human)
negative regulation of activated T cell proliferationGalectin-9Homo sapiens (human)
positive regulation of viral entry into host cellGalectin-9Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityGalectin-9Homo sapiens (human)
maternal process involved in female pregnancyGalectin-9Homo sapiens (human)
positive regulation of activated T cell autonomous cell deathGalectin-9Homo sapiens (human)
ERK1 and ERK2 cascadeGalectin-9Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeGalectin-9Homo sapiens (human)
response to interleukin-1Galectin-9Homo sapiens (human)
cellular response to type II interferonGalectin-9Homo sapiens (human)
positive regulation of transforming growth factor beta productionGalectin-9Homo sapiens (human)
positive regulation of monocyte chemotactic protein-1 productionGalectin-9Homo sapiens (human)
cellular response to virusGalectin-9Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionGalectin-9Homo sapiens (human)
positive regulation of dendritic cell chemotaxisGalectin-9Homo sapiens (human)
negative regulation of CD4-positive, alpha-beta T cell proliferationGalectin-9Homo sapiens (human)
positive regulation of CD4-positive, alpha-beta T cell proliferationGalectin-9Homo sapiens (human)
positive regulation of dendritic cell apoptotic processGalectin-9Homo sapiens (human)
positive regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cellGalectin-9Homo sapiens (human)
positive regulation of dendritic cell differentiationGalectin-9Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathwayGalectin-9Homo sapiens (human)
cellular response to virusGalectin-8Homo sapiens (human)
xenophagyGalectin-8Homo sapiens (human)
lymphatic endothelial cell migrationGalectin-8Homo sapiens (human)
T cell homeostasisGalectin-2Homo sapiens (human)
positive regulation of apoptotic processGalectin-2Homo sapiens (human)
positive regulation of inflammatory responseGalectin-2Homo sapiens (human)
cell-cell adhesionGalectin-2Homo sapiens (human)
positive regulation of dendritic cell differentiationGalectin-1Homo sapiens (human)
plasma cell differentiationGalectin-1Homo sapiens (human)
apoptotic processGalectin-1Homo sapiens (human)
T cell costimulationGalectin-1Homo sapiens (human)
regulation of apoptotic processGalectin-1Homo sapiens (human)
positive regulation of apoptotic processGalectin-1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionGalectin-1Homo sapiens (human)
myoblast differentiationGalectin-1Homo sapiens (human)
positive regulation of viral entry into host cellGalectin-1Homo sapiens (human)
positive regulation of inflammatory responseGalectin-1Homo sapiens (human)
cell-cell adhesionGalectin-1Homo sapiens (human)
positive regulation of dendritic cell differentiationGalectin-3Homo sapiens (human)
monocyte chemotaxisGalectin-3Homo sapiens (human)
mRNA processingGalectin-3Homo sapiens (human)
RNA splicingGalectin-3Homo sapiens (human)
neutrophil chemotaxisGalectin-3Homo sapiens (human)
epithelial cell differentiationGalectin-3Homo sapiens (human)
positive regulation of protein-containing complex assemblyGalectin-3Homo sapiens (human)
regulation of T cell proliferationGalectin-3Homo sapiens (human)
innate immune responseGalectin-3Homo sapiens (human)
negative regulation of endocytosisGalectin-3Homo sapiens (human)
eosinophil chemotaxisGalectin-3Homo sapiens (human)
macrophage chemotaxisGalectin-3Homo sapiens (human)
negative regulation of T cell receptor signaling pathwayGalectin-3Homo sapiens (human)
positive chemotaxisGalectin-3Homo sapiens (human)
regulation of T cell apoptotic processGalectin-3Homo sapiens (human)
mononuclear cell migrationGalectin-3Homo sapiens (human)
positive regulation of mononuclear cell migrationGalectin-3Homo sapiens (human)
positive regulation of calcium ion importGalectin-3Homo sapiens (human)
regulation of extrinsic apoptotic signaling pathway via death domain receptorsGalectin-3Homo sapiens (human)
positive regulation of protein localization to plasma membraneGalectin-3Homo sapiens (human)
negative regulation of protein tyrosine phosphatase activityGalectin-3Homo sapiens (human)
negative regulation of immunological synapse formationGalectin-3Homo sapiens (human)
negative regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cellGalectin-3Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayGalectin-3Homo sapiens (human)
apoptotic processGalectin-7Homo sapiens (human)
heterophilic cell-cell adhesion via plasma membrane cell adhesion moleculesGalectin-7Homo sapiens (human)
antibacterial peptide biosynthetic processGalectin-4Homo sapiens (human)
cell adhesionGalectin-4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (15)

Processvia Protein(s)Taxonomy
galactose bindingGalectin-9Homo sapiens (human)
enzyme bindingGalectin-9Homo sapiens (human)
carbohydrate bindingGalectin-9Homo sapiens (human)
disaccharide bindingGalectin-9Homo sapiens (human)
galactoside bindingGalectin-9Homo sapiens (human)
integrin bindingGalectin-8Homo sapiens (human)
protein bindingGalectin-8Homo sapiens (human)
carbohydrate bindingGalectin-8Homo sapiens (human)
protein bindingGalectin-2Homo sapiens (human)
galactoside bindingGalectin-2Homo sapiens (human)
carbohydrate bindingGalectin-2Homo sapiens (human)
RNA bindingGalectin-1Homo sapiens (human)
protein bindingGalectin-1Homo sapiens (human)
laminin bindingGalectin-1Homo sapiens (human)
lactose bindingGalectin-1Homo sapiens (human)
RNA bindingGalectin-3Homo sapiens (human)
protein phosphatase inhibitor activityGalectin-3Homo sapiens (human)
protein bindingGalectin-3Homo sapiens (human)
IgE bindingGalectin-3Homo sapiens (human)
protein phosphatase bindingGalectin-3Homo sapiens (human)
carbohydrate bindingGalectin-3Homo sapiens (human)
chemoattractant activityGalectin-3Homo sapiens (human)
laminin bindingGalectin-3Homo sapiens (human)
molecular condensate scaffold activityGalectin-3Homo sapiens (human)
disaccharide bindingGalectin-3Homo sapiens (human)
protein bindingGalectin-7Homo sapiens (human)
carbohydrate bindingGalectin-7Homo sapiens (human)
protein bindingGalectin-4Homo sapiens (human)
galactoside bindingGalectin-4Homo sapiens (human)
carbohydrate bindingGalectin-4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
extracellular spaceGalectin-9Homo sapiens (human)
nucleusGalectin-9Homo sapiens (human)
cytoplasmGalectin-9Homo sapiens (human)
cytosolGalectin-9Homo sapiens (human)
collagen-containing extracellular matrixGalectin-9Homo sapiens (human)
nucleusGalectin-9Homo sapiens (human)
cytosolGalectin-9Homo sapiens (human)
extracellular spaceGalectin-8Homo sapiens (human)
cytoplasmGalectin-8Homo sapiens (human)
cytosolGalectin-8Homo sapiens (human)
membraneGalectin-8Homo sapiens (human)
cytoplasmic vesicleGalectin-8Homo sapiens (human)
cytoplasmGalectin-8Homo sapiens (human)
galectin complexGalectin-2Homo sapiens (human)
collagen-containing extracellular matrixGalectin-1Homo sapiens (human)
extracellular regionGalectin-1Homo sapiens (human)
extracellular spaceGalectin-1Homo sapiens (human)
cytoplasmGalectin-1Homo sapiens (human)
endoplasmic reticulum lumenGalectin-1Homo sapiens (human)
cytosolGalectin-1Homo sapiens (human)
collagen-containing extracellular matrixGalectin-1Homo sapiens (human)
extracellular exosomeGalectin-1Homo sapiens (human)
galectin complexGalectin-1Homo sapiens (human)
extracellular spaceGalectin-1Homo sapiens (human)
collagen-containing extracellular matrixGalectin-3Homo sapiens (human)
immunological synapseGalectin-3Homo sapiens (human)
extracellular regionGalectin-3Homo sapiens (human)
extracellular spaceGalectin-3Homo sapiens (human)
nucleusGalectin-3Homo sapiens (human)
nucleoplasmGalectin-3Homo sapiens (human)
cytoplasmGalectin-3Homo sapiens (human)
mitochondrial inner membraneGalectin-3Homo sapiens (human)
cytosolGalectin-3Homo sapiens (human)
plasma membraneGalectin-3Homo sapiens (human)
cell surfaceGalectin-3Homo sapiens (human)
membraneGalectin-3Homo sapiens (human)
secretory granule membraneGalectin-3Homo sapiens (human)
collagen-containing extracellular matrixGalectin-3Homo sapiens (human)
extracellular exosomeGalectin-3Homo sapiens (human)
ficolin-1-rich granule membraneGalectin-3Homo sapiens (human)
spliceosomal complexGalectin-3Homo sapiens (human)
cytoplasmGalectin-3Homo sapiens (human)
immunological synapseGalectin-3Homo sapiens (human)
nucleusGalectin-3Homo sapiens (human)
extracellular spaceGalectin-3Homo sapiens (human)
extracellular spaceGalectin-7Homo sapiens (human)
nucleusGalectin-7Homo sapiens (human)
cytoplasmGalectin-7Homo sapiens (human)
extracellular exosomeGalectin-7Homo sapiens (human)
extracellular spaceGalectin-4Homo sapiens (human)
cytosolGalectin-4Homo sapiens (human)
plasma membraneGalectin-4Homo sapiens (human)
collagen-containing extracellular matrixGalectin-4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (33)

Assay IDTitleYearJournalArticle
AID723486Binding affinity to galectin-3 (unknown origin)2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Tuning the preference of thiodigalactoside- and lactosamine-based ligands to galectin-3 over galectin-1.
AID1628953Competitive binding affinity to recombinant human galectin-2 after 5 mins in presence of fluorescent probe3'-dideoxy-3-[4-(fluorescein-5-yl-carbonylaminomethyl)-1H-1,2,3-triazol-1-yl]-3'-(3,5-dimethoxy-benzamido)-1,1'-sulfanediyl-di-beta-D-galactopyranosi2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
A Selective Galactose-Coumarin-Derived Galectin-3 Inhibitor Demonstrates Involvement of Galectin-3-glycan Interactions in a Pulmonary Fibrosis Model.
AID513982Binding affinity to human galectin 7 at 4 degC by competitive fluorescence polarization assay2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
1H-1,2,3-triazol-1-yl thiodigalactoside derivatives as high affinity galectin-3 inhibitors.
AID71736Inhibitory concentration against Escherichia coli heat-labile enterotoxin (LT) binding to ganglioside GD1b was determined by ELISA assay1999Journal of medicinal chemistry, May-20, Volume: 42, Issue:10
The role of waters in docking strategies with incremental flexibility for carbohydrate derivatives: heat-labile enterotoxin, a multivalent test case.
AID1908325Binding affinity to human galectin-1 by fluorescence polarization analysis2022Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8
Novel Selective Galectin-3 Antagonists Are Cytotoxic to Acute Lymphoblastic Leukemia.
AID1628955Competitive binding affinity to recombinant human galectin-4 N-terminal after 5 mins in presence of fluorescent probe 3,3'-dideoxy-3-[4-(fluorescein-5-yl-carbonylaminomethyl)-1H-1,2,3-triazol-1-yl]-3'-(3,5-dimethoxy-benzamido)-1,1'-sulfanediyl-di-beta-D-g2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
A Selective Galactose-Coumarin-Derived Galectin-3 Inhibitor Demonstrates Involvement of Galectin-3-glycan Interactions in a Pulmonary Fibrosis Model.
AID513981Binding affinity to human galectin 3 at 20 degC by competitive fluorescence polarization assay2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
1H-1,2,3-triazol-1-yl thiodigalactoside derivatives as high affinity galectin-3 inhibitors.
AID1628969Competitive binding affinity to human galectin-7 after 5 mins in presence of fluorescent probe by fluorescence polarization assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
A Selective Galactose-Coumarin-Derived Galectin-3 Inhibitor Demonstrates Involvement of Galectin-3-glycan Interactions in a Pulmonary Fibrosis Model.
AID723493Binding affinity to galectin-3 (unknown origin) by fluorescence polarization assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Tuning the preference of thiodigalactoside- and lactosamine-based ligands to galectin-3 over galectin-1.
AID412876Binding affinity to galectin 3 at 20 degC by fluorescence polarization assay2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Galectin-inhibitory thiodigalactoside ester derivatives have antimigratory effects in cultured lung and prostate cancer cells.
AID1628968Competitive binding affinity to human galectin-3 after 5 mins in presence of fluorescent probe by fluorescence polarization assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
A Selective Galactose-Coumarin-Derived Galectin-3 Inhibitor Demonstrates Involvement of Galectin-3-glycan Interactions in a Pulmonary Fibrosis Model.
AID1628970Competitive binding affinity to human galectin-8 N-terminal after 5 mins in presence of fluorescent probe by fluorescence polarization assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
A Selective Galactose-Coumarin-Derived Galectin-3 Inhibitor Demonstrates Involvement of Galectin-3-glycan Interactions in a Pulmonary Fibrosis Model.
AID513984Binding affinity to human galectin 9 N-terminal domain at 20 degC by competitive fluorescence polarization assay2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
1H-1,2,3-triazol-1-yl thiodigalactoside derivatives as high affinity galectin-3 inhibitors.
AID412878Binding affinity to galectin 8N terminal domain at 20 degC by fluorescence polarization assay2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Galectin-inhibitory thiodigalactoside ester derivatives have antimigratory effects in cultured lung and prostate cancer cells.
AID1908329Binding affinity to human galectin-4C (171 to 323 residues) expressed in Escherichia coli BL21 by competitive fluorescence anisotropy assay2022Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8
Novel Selective Galectin-3 Antagonists Are Cytotoxic to Acute Lymphoblastic Leukemia.
AID513983Binding affinity to human galectin 8 N-terminal domain at 20 degC by competitive fluorescence polarization assay2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
1H-1,2,3-triazol-1-yl thiodigalactoside derivatives as high affinity galectin-3 inhibitors.
AID723494Binding affinity to galectin-1 (unknown origin) by fluorescence polarization assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Tuning the preference of thiodigalactoside- and lactosamine-based ligands to galectin-3 over galectin-1.
AID1628967Competitive binding affinity to rat galectin-1 after 5 mins in presence of fluorescent probe by fluorescence polarization assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
A Selective Galactose-Coumarin-Derived Galectin-3 Inhibitor Demonstrates Involvement of Galectin-3-glycan Interactions in a Pulmonary Fibrosis Model.
AID1628960Competitive binding affinity to recombinant human galectin-9 C-terminal after 5 mins in presence of fluorescent probe 3,3'-dideoxy-3-[4-(fluorescein-5-yl-carbonylaminomethyl)-1H-1,2,3-triazol-1-yl]-3'-(3,5-dimethoxy-benzamido)-1,1'-sulfanediyl-di-beta-D-g2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
A Selective Galactose-Coumarin-Derived Galectin-3 Inhibitor Demonstrates Involvement of Galectin-3-glycan Interactions in a Pulmonary Fibrosis Model.
AID412875Binding affinity to galectin 1 at 20 degC by fluorescence polarization assay2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Galectin-inhibitory thiodigalactoside ester derivatives have antimigratory effects in cultured lung and prostate cancer cells.
AID1628971Competitive binding affinity to human galectin-9 N-terminal after 5 mins in presence of fluorescent probe by fluorescence polarization assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
A Selective Galactose-Coumarin-Derived Galectin-3 Inhibitor Demonstrates Involvement of Galectin-3-glycan Interactions in a Pulmonary Fibrosis Model.
AID1908327Binding affinity to human galectin-8N by fluorescence polarization assay2022Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8
Novel Selective Galectin-3 Antagonists Are Cytotoxic to Acute Lymphoblastic Leukemia.
AID1628956Competitive binding affinity to recombinant human galectin-4 C-terminal after 5 mins in presence of fluorescent probe 2-(fluorescein-5/6-yl-carbonyl)-aminoethyl 2-acetamido-2-deoxy-alpha-D-galactopyranosyl-(1-3)-[alpha-L-fucopyranosyl-(1-2)]-beta-D-galact2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
A Selective Galactose-Coumarin-Derived Galectin-3 Inhibitor Demonstrates Involvement of Galectin-3-glycan Interactions in a Pulmonary Fibrosis Model.
AID412884Binding affinity to galectin 7 at 0 degC by fluorescence polarization assay2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Galectin-inhibitory thiodigalactoside ester derivatives have antimigratory effects in cultured lung and prostate cancer cells.
AID412879Binding affinity to galectin 9N terminal domain at 0 degC by fluorescence polarization assay2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Galectin-inhibitory thiodigalactoside ester derivatives have antimigratory effects in cultured lung and prostate cancer cells.
AID723485Selectivity ratio for human galectin-1 to human galectin-32013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Tuning the preference of thiodigalactoside- and lactosamine-based ligands to galectin-3 over galectin-1.
AID723490Selectivity ratio of Kd for galectin-1 (unknown origin) to Kd for galectin-3 (unknown origin)2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Tuning the preference of thiodigalactoside- and lactosamine-based ligands to galectin-3 over galectin-1.
AID1908328Binding affinity to human galectin-4N using 3,3'-dideoxy-3-[4-(fluorescein-5-yl-carbonylaminomethyl)-1H-1,2,3-triazol-1-y1]-3'-(3,5-dimethoxy-benzamido)-1,1'-sulfanediyl-di-beta-D-galactopyranoside as fluorescent probe by fluorescence polarization analysi2022Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8
Novel Selective Galectin-3 Antagonists Are Cytotoxic to Acute Lymphoblastic Leukemia.
AID1908326Binding affinity to human galectin-3 by fluorescence polarization assay2022Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8
Novel Selective Galectin-3 Antagonists Are Cytotoxic to Acute Lymphoblastic Leukemia.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB1997Structure (London, England : 1993), Nov-15, Volume: 5, Issue:11
Structural foundation for the design of receptor antagonists targeting Escherichia coli heat-labile enterotoxin.
AID1811Experimentally measured binding affinity data derived from PDB1997Structure (London, England : 1993), Nov-15, Volume: 5, Issue:11
Structural foundation for the design of receptor antagonists targeting Escherichia coli heat-labile enterotoxin.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2013Chembiochem : a European journal of chemical biology, Jul-22, Volume: 14, Issue:11
Investigation into the feasibility of thioditaloside as a novel scaffold for galectin-3-specific inhibitors.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2010Cancer letters, Dec-28, Volume: 299, Issue:2
Galectin inhibitory disaccharides promote tumour immunity in a breast cancer model.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (71)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (19.72)18.7374
1990's15 (21.13)18.2507
2000's15 (21.13)29.6817
2010's22 (30.99)24.3611
2020's5 (7.04)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.66 (24.57)
Research Supply Index4.32 (2.92)
Research Growth Index4.64 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (5.41%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other70 (94.59%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]